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In search for antitumor metal-based drugs that would mitigate the severe side-effects of cisplatin, 
Ru(II) complexes are gaining increasing recent interest. In this work, we report on the synthesis, 
characterization (
1
H- and 
13
C-NMR, FT-IR) and cytotoxicity studies of two new half-sandwich 
organometallic Ru(II) complexes of the general formula [Ru(η6-arene)(XY)Cl](PF6) where arene 
= benzene or toluene and XY = bidentates: dipyrido[3,2-a:2′,3′-c]phenazine (dppz) or 
2-(9-anthryl)-1H-imidazo[4,5-f][1,10]phenanthroline (aip), which are bound to Ru(II) via two 
phenanthroline-N atoms in a characteristic "piano-stool" configuration of Ru(II)-arene 
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complexes - as confirmed by vibrational and NMR spectra. In addition, cytotoxic studies were 
performed for similar half-sandwich organometallic [Ru(η6-p-cymene)(Me2dppz)Cl]PF6 complex 
(Me2dppz = 11,12-dimethyl-dipyrido[3,2-a:2′,3′-c]phenazine). This study is complemented with 
elaborate modeling with density functional theory (DFT) calculations, which provided insight 
into reactive sites of Ru(II) structures, further detailed by Molecular Docking on the B-DNA 
dodecamer, which identified binding sites and affinities: most pronounced for the 
[Ru(η6-benzene)(aip)Cl](PF6) in both A-T and G-C regions of the DNA minor groove. Cytotoxic 
activity was probed versus tumor cell lines B16, C6 and U251 (B16 mouse melanoma, C6 rat 
glioma, U251 human glioblastoma) and non-tumor cell line HACAT (HACAT normal human 
keratinocytes). 
 
Keywords: Ruthenium complexes; DNA Docking; Cytotoxicity studies; DFT Calculations; 
Intercalation 
 
1. Introduction 
The class of platinum compounds comprising cisplatin, carboplatin and oxaliplatin are the most 
widely known metal-based anticancer drugs [1]. Although cisplatin and its derivatives have had 
significant success in treatment of a vast majority of tumors, they are also toxic for non-cancer 
cells, have a limited range of activity, reduction of efficacy caused by drug resistance, and 
significant side-effects [2]. Despite great efforts to develop other less toxic but equally effective 
platinum-based drugs, clinical trials often show that these complexes have similar disadvantages 
as those associated with cisplatin therapy [3]. Due to these limitations, research of new 
anticancer drugs is increasingly focused on complexes with other metals, among which 
ruthenium complexes have raised great attention. Various ruthenium complexes have been tested 
against a number of cancer cell lines [4], and the three Ru(III) complexes: NAMI-A 
(ImH)[trans-Ru(Im)(DMSO)Cl4] ((Im = imidazole, DMSO = dimethylsulfoxide) [5], KP1019 
[trans-tetrachloro-bis-(1H-indazole)-ruthenate(III)] [6], and its more soluble sodium salt, 
NKP 1339 trans-[Ru(Ind)2Cl4](IndH) (Ind = indazole) have entered clinical trials [7]. Ru(III) 
complexes are in general thermodynamically and kinetically less stable than Ru(II) complexes, 
while the nature of ligands and net charge has a significant impact on the kinetics of the 
hydration of Ru(II/III) complexes [8, 9]. Also, based on the reachable Ru(II/III) redox potential 
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in vivo, the antitumor properties of the Ru(III) complexes are related to their reduced oxidation 
state, to Ru(II). Consequently, many Ru(II) complexes have attracted interest as promising 
anticancer agents and the Ru(II)-polypyridyl compound, TLD-1433, recently entered phase IB 
clinical trials [9]. 
Recent research has focused on promising anticancer properties of organometallic 
ruthenium(II)-arene compounds of the type [(η6-arene)Ru(XY)(Z)], also referred to as “piano-
stool” structures, where XY is a bidentate chelating ligand and Z is a leaving group [10]. These 
half-sandwich complexes are very attractive due to diverse possibilities for derivatization at the 
arene moiety, introduction of two mono- or one bidentate ligand at the XY-site, as well as 
functionalization with numerous biologically active groups [11]. Furthermore, the hydrophobic 
arene ring facilitates admittance of Ru(II) complexes into cells and contributes to their stability 
[9]. A recent study of a series of Ru(II)-arene Schiff-base (RAS) complexes has shown that the 
RAS complexes with more hydrophobic ligands have higher intercellular accumulation (1,3,5-
trimethylbenzene > benzene, methylbenzene) [9, 11]. Our previous report also indicated that 
p-cymene as arene ligand and the planar aromatic Me2dppz (Me2dppz = 11,12-
dimethyldipyrido[3,2-a:2′,3′-c]phenazine) as XY ligand facilitate transport of the complex cation 
across the cell membrane which may contribute to DNA binding [12]. In addition, our cytotoxic 
activity studies revealed that the complex had a significantly higher cytotoxic activity and DNA-
binding properties than cisplatin. Therefore, further studies of Ru(II)-arene complexes with 
intercalating ligands such as dppz were pursued with the aim at increasing our understanding of 
promising anticancer reactivity. In this paper, we present the synthesis, characterization, and 
biological evaluation of two new “piano stool” ruthenium(II)-arene complexes, complemented 
with theoretical studies using density functional theory (DFT) and molecular docking 
methodology. Besides two similar complexes are studied by DFT and their cytotoxic activity was 
determined for comparison reasons. 
 
2. Experimental 
2.1. Materials 
All chemicals were of reagent-grade quality or higher, were obtained from commercial suppliers 
and were used without purification. Solvents were used as received. RuCl3 was purchased from 
Acros Organics. 
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2.2. Instrumentation and methods 
1
H and 
13
C NMR spectra were recorded in deuterated solvents on a Bruker Ultrashield Advance 
III spectrometer 500 (
1
H: 500 MHz, 
13
C: 126 MHz) at room temperature. The residual solvent 
peaks have been used as an internal reference. Infrared spectra were recorded on a Nicolet 6700 
FT-IR spectrometer using the ATR technique. ESI mass spectra measurements of complexes 
were carried out on a MS system LTQ Orbitrap XL with heated ESI ionization in methanol 
solutions. UV-vis spectra were recorded on GBC Cintra 40 spectrophotometer. 
 
2.3. Synthesis 
The ligands 11,12-dimethyldipyrido[3,2-a:2′,3′-c]phenazine (Me2dppz) and dipyrido[3,2-a:2',3'-
c]phenazine (dppz) were synthesized by condensation of 1,10-phenathroline-5,6-dione [13] with 
4,5-dimethylbenzene-1,2-diamine or o-phenylenediamine according to a published procedure 
[14]. The ligand 2-(9-anthryl)-1H-imidazo[4,5-f][1,10]phenanthroline (aip) was prepared by 
condensation of the same dione with 9-anthraldehyde under conditions described in the literature 
[15]. The ruthenium dimers [(η6-p-cymene)RuCl2]2, [(η
6
-toluene)RuCl2]2 and 
[(η6-benzene)RuCl2]2 were prepared according to a published procedure [16]. Complex [Ru(η
6
-p-
cymene)(Me2dppz)Cl](PF6) (2) [12] was synthesized according to a published procedure. 
 
[Ru(η6-toluene)(dppz)Cl](PF6) (1) 
To a suspension of [(η6-toluene)RuCl2]2 (167 mg, 0.316 mmol) in 15 mL of methanol a solution 
of dppz (179 mg, 0.632 mmol) in 15 mL of dichloromethane was added dropwise. The reaction 
mixture was stirred for 6 h at room temperature and filtered. Then NH4PF6 (155 mg, 
0.948 mmol) was added to the solution that was left stirring overnight. The pale yellow 
precipitate was filtered off, washed with cold MeOH and Et2O and dried in vacuo. Yield: 
256 mg, 62%. 
1H NMR (500 MHz, DMSO) δ(ppm): 10.03 (d, J = 4.2 Hz, 2H), 9.51 (d, J = 
7.7 Hz, 2H), 8.25 (dd, J = 18.6, 12.5 Hz, 4H), 7.98 (s, 2H), 6.51 (s, 2H), 6.14 (d, J = 5.2 Hz, 2H), 
5.96 (s, 1H), 2.34 (s, 3H). 
13
C NMR (126 MHz, DMSO) δ(ppm): 157.49, 147.97, 141.64, 138.74, 
135.15, 132.40, 129.20, 129.10, 127.47, 105.84, 90.13, 83.00, 80.26, 18.89. IR (ATR, cm
-1
): 
3097 (w), 2988 (w), 2942 (w), 1497 (w), 1442 (w), 1411 (w), 1356 (w), 833 (s), 731 (w), 
556 (w). UV-vis (nm, DMSO): 278, 318, 364, 382. ESI-MS (in DMSO, m/z): 511.1 ([M-PF6]
+
). 
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[Ru(η6-p-benzene)(aip)Cl](PF6) (3) 
To a suspension of [(η 6-benzene)RuCl2]2 (18 mg, 0.036 mmol) in 5 mL of methanol was added 
dropwise a solution of aip (27 mg, 0.068 mmol) in 5 mL of dichloromethane. The reaction 
mixture was stirred for 5 h at room temperature and filtered. Then NH4PF6 (18 mg, 0.110 mmol) 
was added to the solution and left overnight with stirring. The pale yellow precipitate was 
filtered, washed with cold MeOH and Et2O and dried in vacuo. Yield: 50 mg, 97%. 
1
H NMR 
(200 MHz, DMSO) δ(ppm): 14.82 (s, 1H), 10.02 (dd, J = 5.3, 1.0 Hz, 2H), 9.18 (s, 2H), 8.96 (s, 
1H), 8.24 (m, 4H), 7.76 (d, J = 8.5 Hz, 2H), 7.58 (dt, J = 14.9, 6.2 Hz, 5H), 6.38 (d, J = 7.4 Hz, 
6H).
13
C NMR (50 MHz, DMSO) δ(ppm): 153.92, 150.66, 143.31, 132.44, 130.82,130.64, 
129.61, 128.64, 127.31, 126.39, 125.83, 125.49, 124.40, 104.02, 86.23. IR (ATR, cm
−1
): 
3640(w), 3060 (m), 2970 (m), 2930 (m), 1607 (w), 1544 (w), 1507 (w), 1447 (w), 1413 (w), 
1365 (w), 839 (s), 742 (m), 556 (w). UV-vis (nm, DMSO): 254, 294, 342, 360, 378. ESI-MS (in 
DMSO, m/z): 611.1 ([M-PF6]
+
). 
 
 
Scheme 1. Synthesis of 1 and 3. 
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Scheme 2. Structure of the complexes. 
 
2.4. Computational details 
All complexes were optimized at the DFT level with the hybrid wB97XD functional, a 
LANL2DZ effective core potential for Ru ion, and a 6-311G(d) basis set for all other atoms, 
without symmetry constraints. The same level was used for the frequency calculations and 
confirmation that optimized geometry has only real frequencies. The gas phase structures of 1 
and 3 were re-optimized in DMSO, simulated by the universal solvation model (SMD) [17]. 
Calculated electronic transitions were carried out within the time dependent density functional 
theory (TD-DFT) approach, using the same functional, the basis sets and the solvent. 
The quantum chemical calculations were done with Gaussian09 software [18]. The 
condensed Fukui function is calculated from eqns. 1-3, where qN, qN-1 and qN+1 are the partial 
charge of the atom A in neutral, anionic and cationic forms, respectively. 
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nucleophilic attack:                                                                   (1) 
 
electrophilic attack:                                  (2) 
 
radical attack:              (3) 
 
The condensed dual descriptor is calculated from eqn. 4.
 
 (4) 
 
The NPA [19] and Mulliken [20] partial atomic charges were used to calculate values of 
condensed Fukui function and condensed dual descriptor at the ground state geometry in 
vacuum. Calculations were carried on the PARADOX supercomputing facility [21]. 
 
2.5. Molecular docking 
Docking of flexible ligands (Ru(II) complexes) against rigid receptor molecule (B-DNA) were 
performed using the AutoDock suite of programs (AutoDock 4.2) [22]. 
The DFT optimized structures of 1-3 at wB97XD/6-311G(d)/LANL2DZ levels of theory 
were used. The crystal data of the B-DNA dodecamer d(CGCGAATTCGCG)2 (PDB ID:1BNA) 
were downloaded from the Protein Data Bank. The water molecules were removed from the 
1BNA and Gasteiger charges were added to the complexes by Autodock 4.2 Tools (ADT) before 
performing docking calculations. The binding site was centered on the DNA molecule and a grid 
box was created so that it involved the entire DNA molecule. The most stable docked ligand 
conformations were found by performing the rigid docking protocol and 10 runs of the 
Lamarckian genetic algorithm. 
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2.6. Cell culture 
Mouse melanoma (B16), rat glioma (C6), human glioblastoma (U251) and human keratinocytes 
(HACAT) were obtained from European Collection of Cell Cultures ECACC. For experiments, 
cells were grown in RPMI-1640 medium and high glucose DMEM medium supplemented with 
5% (RPMI-1640) and 10% FCS (DMEM), glutamate and antibiotics (culture medium) at 37 °C 
in a humidified atmosphere with 5% CO2. Cells were prepared using trypsinization procedure 
with trypsin/EDTA and seeded in Perti dishes (10 cm, 2.5x10
6 
cells) and flat-bottom 96-well 
tissue culture plates (15×10
4
 cells/well) for viability assays (Sarstedt, Numbrecht, Germany). 
For the biological examination, 1-3 were dissolved in DMSO, as a 100 mM stock 
solution. This solution was further dissolved in appropriate cell culture media, depending on cell 
culture used in experiment. The DMSO concentration in maximal concentration of extract (1 
mM) prepared for cell treatment was 1%. Cells were treated in serial solutions (from 1 mM to 
0.015 mM, prepared in culture medium) and after 24 h cell viability was determined using MTT 
and Crystal violet methods. 
 
2.7. Trypan blue exclusion assay 
Trypan blue exclusion assay was used to determine the number of viable cells present in a cell 
suspension. Viable cells with intact membranes exclude trypan blue dye and appear with clear 
cytoplasm, whereas non-viable cells do not, and cytoplasm remains blue. Cell suspension 
(20 μL) was mixed with 180 μL of filtered TB solution (0.4%) and cell number was determined 
using a hemocytometer. 
 
2.8. Cytotoxicity studies 
Cell viability was measured using assays for adherent cell lines, MTT and Crystal violet (CV). 
MTT assay is based on the ability of metabolically viable cells to bind and reduce MTT to 
formazan crystals in mitochondria. Cells were incubated with MTT (0.5 mg/mL) for 1.5 h after 
which MTT was removed and formazan crystals were dissolved with DMSO. The absorbances 
were measured by an automated microplate reader at 570 nm, and the results were presented as 
% of viability relative to untreated control cultures (viability 100%). 
For CV assay, after 24 h treatment, cell cultures were washed with PBS, fixed with 
methanol and incubated for 10 min with 1% crystal violet dye. After incubation, plates were 
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washed with water and CV bound to the proteins was dissolved in 33% acetic acid. The 
absorbance was measured in an automated microplate reader at 570 nm (Sunrise, TECAN, UK). 
The absorbance values are correlated to the number of viable cells. Results were presented as % 
of viability relative to untreated control cultures (viability 100%). 
Viability assays were used to calculate IC50 value, which represents the concentration that 
leads to decrease in cell viability for 50% comparing to untreated cells. IC50 value was calculated 
using GraphPad Prism program. 
 
3. Results and discussion 
3.1. Characterization of the complexes 
Complexes were synthesized following the synthetic routes described in scheme 1 and published 
procedures. The resulting complexes were soluble in DMSO. All complexes were characterized 
by 
1
H and 
13
C NMR and IR (figures S1-S6). 
1
H and 
13
C NMR spectra of the complexes suggest 
"piano-stool" geometry. As determined by the integrals of the 
1
H NMR spectra, the arene to 
dppz/Me2dppz/aip ratio was 1:1. 
 
3.2. Stability of the complexes in DMSO and DMSO/D2O solution 
In order to check whether the complexes are stable towards ligand exchange in DMSO solutions 
[23] we have followed their 
1
H-NMR spectra in DMSO-d6 and did not find any noticeable 
change over 48 h (figures S7 and S8). Therefore, DMSO solutions were used as stock solutions 
for cytotoxicity experiments. In addition, the stability of complexes in DMSO/D2O mixture was 
also followed by 
1
H-NMR spectroscopy (figures S9 and S10). Also, this experiment showed no 
change in spectra. 
 
3.3. Geometry optimization 
The initial geometry of Ru complex, labelled as ‘Model System’ (MS), was taken from the single 
crystal X-ray data [24] and subjected to optimization at the DFT level with several functionals 
and basis sets (table 1). The performance of three functionals without dispersion (B3LYP 
[25, 26], CAM-B3LYP [27] and TPSS [28]) and two which include dispersion (B97D [29] and 
wB97XD [30]), have been tested in reproducing molecular structures. Different basis sets were 
applied for the ligands: 6-31G(d) [31, 32], 6-31G(d,p) [33], 6-31G++(d) and 6-31G+(d) [34, 35], 
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6-311G(d) [36, 37], as well as for the metal ion: Lanl2dz with effective core potentials (EPC) 
[38] and SDD EPC [39]. 
Within the B3LYP functional, additional p-type polarization functions on the atoms of 
ligands have no significant effect on the reproduction of structural parameters. Application of the 
6-31G++(d) basis set that adds diffuse functions on each of the ligands atoms leads to a 
significant increase of Ru-centroid and Ru-Cl distance. We have found that the use of SDD EPC 
basis set for metal ion yields slightly better reproduction of experimental structural parameters. 
The metal-ligand distances obtained using CAM-B3LYP, TPSSTPSS, B97D and wB97XD 
functionals are better in comparison to B3LYP, whereas the combination 
wB97XD/6-311G(d)/Lanl2dz does give the closest agreement with experimental values (table 1). 
The results are consistent with conclusions of extensive theoretical studies of similar Ru(II) 
compounds [40]. 
According to these results (table 1), the combination of functional and basis sets 
wB97XD/6-311G(d)/Lanl2dz appears to be the most appropriate for reproducing the X-ray 
structure of complex MS. Therefore, it was adopted for optimization of all investigated Ru(II) 
complexes. Their optimized molecular structures are represented in figure 1, while table 2 lists a 
comparison of important bond distances and angles. As can be noticed, there are no major 
changes in bond and angle parameters upon varying the diimine and arene co-ligands. 
In all monocationic complexes the dppz ligand or its derivatives is coordinated to Ru(II) 
ion through the nitrogen atoms in a bidentate manner, forming a five-membered metallacycle. 
The Ru(II) complexes have distorted pseudo-octahedral geometry which consists of two nitrogen 
atoms and the chloride atom, which refer to the legs of the stool, while the η6-arene ring forms 
the seat of the “three-legged piano stool” structure. Such piano-stool geometry is already 
observed and reported in many half-sandwich ruthenium(II)-arene complexes [41]. All bond 
lengths calculated by the present DFT method are in good agreement with available experimental 
data. Also, calculated bond lengths fall within the reported values for similar half-sandwich 
Ru(II) complexes, which ranged from 2.076 Å to 2.112 Å for Ru-N, from 2.380 Å to 2.415 Å for 
Ru-Cl, and from 2.150 Å to 2.211 Å for Ru-C [8, 42]. The bite angle of N-Ru-N is lower than 
the bond angles involving chloride ion N-Ru-Cl as experimentally already observed [42a]. These 
angular values near 90° are commonly quoted as evidence of piano stool structure [42b]. 
Experimental spectra of 1 and 3 recorded in DMSO solution were compared with the calculated 
Ac
c
pt
 M
an
us
cri
pt
11 
spin-allowed electronic transitions (figures S11 and S12). The nature of the singlet-singlet 
transitions responsible for the absorption bands was assigned using TD-DFT calculations. 
 
The absorption spectra of the newly synthesized ruthenium(II) complexes (1 and 3) 
exhibited two sets of the absorption bands. The very intense bands in the UV region of 220-
300 nm could be assigned to the intraligand π–π* transitions. Also, 1 and 3 showed weak 
absorption bands in the range of 300-400 nm which correspond to MLCT (metal to ligand charge 
transfer) transitions [41a, 43]. Composition of MOs (figures S11 and S12) involved in major 
calculated transitions confirmed such assignation of the absorption bands. 
 
3.4. Reactivity analysis 
An analysis of the frontier molecular orbitals involved consideration of the HOMO orbitals as 
nucleophilic or electron donating and the LUMO orbitals as electrophilic and electron accepting. 
Figure 2 shows graphic representations of the calculated HOMO and LUMO orbitals for 
investigated Ru(II) complexes. The composition of MOs are very similar for MS, 1 and 2. The 
LUMO orbitals of these complexes have a contribution mainly from the dppz ligand or its 
derivatives. The main contribution to the HOMO orbitals of these complexes derives from the 
chloride atom, metal center and η6-arene ring. The situation is quite different for 3. The dppz 
ligand, the chloride atom and metal center have participation in the LUMO orbitals, while 
anthracene group almost entirely contribute to HOMO orbitals. These differences of MOs 
composition may cause different reactivity of investigated complexes. 
Based on Parr and Yang [44] theory we studied molecular reactivity of Ru(II) complexes 
by calculating Fukui functions. The reactivity of sites in a chemical species is best viewed 
through the Fukui functions: f 
+
 for the nucleophilic, f 
–
 for the electrophilic, f 
0
 for the radical 
attack and dual descriptor Δf, considering the NPA and Mulliken charges (see Computational 
methodology). Unlike Fukui function, Δf reveals both types of reactive sites. If Δf  > 0, then the 
site is favorable for a nucleophilic attack, whereas if Δf < 0, then the site is favorable for an 
electrophilic attack. 
As shown in table 3, Ru and Cl are the only reactive centers for MS and these atoms are 
favorable for an electrophilic and radical attack. The most reactive sites of the molecule upon 
nucleophilic attack are C9 and C22 atoms of dppz ligand and Cl atom for radical attack. In the 
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case of 1, the asymmetric substitution of benzene ring leads to the appearance of new reactive 
centers for nucleophilic attack (C21, C23). Complex 2 has the reactive sites for nucleophilic 
attack at C9 and C24, due to para substituted benzene ring. Additional methyl group of dppz 
ligand may be responsible for the new reactive centers, C14 and C19, which are the most 
favorable for an electrophilic and radical attack. Also, 3 has similar reactive sites of aip ligand 
upon nucleophilic attack (C9, C10, C30, C31), but the most favorable centers for an electrophilic 
attack are located on the anthracene group (C14, C21). The main difference in the values of the 
Fukui functions calculated using the NPA and Mulliken charges can be noted for the metal ion, 
but the values for other atoms have the same trends. 
 
3.5. Molecular docking with DNA 
In order to explore the most feasible binding sites, interaction modes, and binding affinities 
docking studies have been performed on the Ru(II) complexes (1-3) with B-DNA (PDB ID: 
1BNA). The docked model (figure 3) revealed that 1 and 2 were tailored tightly into the curved 
contour of the targeted DNA minor groove within A-T rich region, in such a way that planar part 
of the aromatic rings made favorable electrostatic (π-anion) and hydrophobic (π-sigma) contacts 
with the DNA functional groups. Complex 3 interacts with DNA through electrostatic (π-anion) 
and hydrophobic (π-sigma) interactions at the minor groove with an affinity to both A-T and G-C 
region. 
The resulting binding energies of docked structures were -8.50, -8.52 and -10.09 kcal/mol 
for 1-3, respectively, indicating the higher binding affinity between DNA and 3 as compared to 1 
and 2. In addition, the results indicate that there are certain hydrogen-bonding interaction 
between 1-2 and DNA. The length of these hydrogen bonds are 2.201 Å (H (DA-6)/N3 (ligand) 
for 1 and 2.266 Å (N (DA-6)/H3 (N4)) for 2. 
 
3.6. Cytotoxic activity of the complexes 
The cytotoxicity of the complexes was studied in three cancer cell lines B16, C6, U251 and 
normal human ketatinocytes cell line, HACAT. As shown in table 4, cell lines show different 
sensitivity on the treatment. 
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Regarding the treatment with 1, HACAT cell line was sensitive (IC50 = 0.06 mM) while 
among tumor cell lines, only in B16 cell viability was decreased below 50%, which is a 
necessary condition for the calculation of IC50 values (IC50 = 0.5 mM). 
Treatment with 2 exerted cytotoxic effect only on tumor cell lines where U251 and C6 
were more sensitive (IC50 for both cell lines was 0.125 mM) in comparison to B16 (IC50 = 1 mM, 
which is the highest concentration used for treatment). 
Complex 3 exerted cytotoxic effect only on HACAT cell line (IC50 = 0.83 mM), while all 
tumor cell lines remained unsensitive (IC50 >1 mM). 
 
4. Conclusion 
In this study, half-sandwich Ru(II)-arene complexes have been synthesized, characterized and 
their geometry has been optimized. Cytotoxic studies on three human tumor cell lines (B16, C6 
and U251) and one non-tumor in vitro cell model (HACAT) revealed moderate cytotoxic 
activity. Molecular docking experiments revealed intercalating potential to nuclear DNA. 
Organic agents that strongly bind DNA via intercalation are extremely successful anticancer 
agents. However, as shown in this study, this strong DNA intercalation is not a crucial 
interaction responsible for cytotoxic activity. Further structure-activity study in our laboratories 
will be directed toward obtaining complexes with a higher selectivity. 
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Figure 1. The optimized molecular structures of investigated Ru(II) complexes. 
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Figure 2. Graphic representations of the calculated HOMO and LUMO orbitals for investigated 
Ru(II) complexes. 
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Figure 3. Snapshots of the most preferable binding sites of Ru(II) complexes with B-DNA. 
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Table 1.  DFT calculated bond lengths (Å) for MS using several functionals and basis sets 
and corresponding experimental values. 
No.   Ru-centroid Ru-Cl Ru-N(dppz)* 
      
 Experimental data  1.703 2.411 2.112 
      
1 B3LYP  6-31G(d): C H N Cl 
Lanl2dz: Ru 
1.819 2.422 2.116 
      
2 B3LYP 
 
6-31G(d): Cl H N  
6-311G(d): C  
Lanl2dz: Ru 
1.807 2.419 2.124 
      
3 B3LYP  Lanl2dz: All atoms 1.866 2.454 2.082 
      
4 B3LYP 
 
6-31G(d,p): C H N Cl 
Lanl2dz: Ru 
1.819 2.422 2.116 
      
5 B3LYP  6-31G++(d): C H N Cl 
Lanl2dz: Ru 
1.871 2.457 2.094 
      
6 B3LYP  6-31G(d): C H N Cl 
SDD: Ru 
1.776 2.405 2.116 
      
7 CAM-B3LYP 6-31G(d): C H N Cl 
Lanl2dz: Ru 
1.793 2.402 2.111 
      
8 TPSSTPSS 
 
6-31G(d): C H N Cl 
Lanl2dz: Ru 
1.753 2.408 2.127 
      
9 B97D  
 
6-31G(d): C H N Cl 
Lanl2dz: Ru 
1.753 2.423 2.103 
      
10 B97D  
 
6-31G(d): H N Cl 
6-31G+(d): C 
Lanl2dz: Ru 
1.753 2.423 2.103 
      
11 wB97XD  
 
6-31G(d,p): C H N Cl 
Lanl2dz: Ru 
1.746 2.406 2.120 
      
12 wB97XD  
 
6-311G(d): C H N Cl 
Lanl2dz: Ru 
1.733 2.409 2.125 
* Average values 
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Table 2. Comparison of the calculated bond lengths (Å) and angles () obtained for the 
complexes, using wB97XD/6-311G(d) for C H N Cl, and Lanl2dz for Ru, with the 
corresponding experimental values. 
  Complexes 
  MS  1 2 3 
Distance (Å)  Exp. Calc. 
Ru-N(dppz)*  2.112 2.125 2.115 2.115 2.112 
Ru-Cl1  2.411 2.409 2.403 2.404 2.399 
Ru-C(arene)*  2.220 2.244 2.232 2.228 2.227 
Ru-centroid  1.705 1.733 1.726 1.720 1.721 
Angle ()       
N1-Ru1-N2  76.71 76.70 77.25 77.20 77.37 
N(dppz)-Ru-Cl*  86.90 84.21  83.44 83.83 83.71 
*Average values 
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Table 3. Values of the Fukui function and dual descriptor (a.u.) for Ru(II) complexes. 
Complex  Ru Cl     
  NPA Mull. NPA Mull.     
MS    f 
+
 0.07 0.03 0.14 0.15     
    f 
–
 0.24 0.07 0.22 0.22     
 Δ f -0.17 -0.04 -0.08 -0.07     
   f 
0
 0.15 0.05 0.18 0.19     
  Ru Cl C21, C23   
1  NPA Mull NPA Mull NPA Mull   
    f 
+
 -0.03 -0.07 0.03 0.04 0.14 0.11   
    f 
–
 0.15 0.00 0.30 0.28 0.02 0.01   
 Δ f -0.18 -0.07 -0.28 -0.24 0.13 0.09   
   f 
0
 0.06 -0.03 0.16 0.16 0.07 0.06   
  Ru Cl C9, C24 C14, C19 
2  NPA Mull NPA Mull NPA Mull NPA Mull 
    f 
+
 -0.03 -0.07 0.02 0.04 0.10 0.06 0.00 0.02 
    f 
–
 -0.02 -0.04 0.01 0.02 0.01 0.01 0.22 0.13 
 Δ f -0.01 -0.03 0.02 0.02 0.08 0.05 -0.21 -0.11 
   f 
0
 -0.02 -0.05 0.02 0.03 0.05 0.03 0.11 0.07 
  Ru Cl C9, C10, C30, C31 C14, C21 
3  NPA Mull NPA Mull NPA Mull NPA Mull 
    f 
+
 -0.03 -0.08 0.04 0.06 0.09 0.06 0.02 0.01 
    f 
–
 -0.01 -0.03 0.00 0.01 0.01 0.01 0.16 0.08 
 Δ f -0.02 -0.05 0.03 0.05 0.09 0.06 -0.11 -0.07 
   f 
0
 -0.02 -0.06 0.02 0.03 0.05 0.03 0.08 0.05 Ac
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Table 4. Cytotoxic effect of the compounds on selected cell lines. 
Compounds IC50 values (mM) 
 B16 C6 U251 HACAT 
1 0.5 >1 >1 0.06 
2 1 0.125 0.125 >1 
3 >1 >1 >1 0.83 
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